Stock Rating Downgrade
The Value Trend Rating for Takeda Pharmaceutical Co Ltd (NYSE: TAK) weakened of late from B to C reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included in our next report.
Recent Price Action
Takeda Pharmaceutical Co Ltd (NYSE: TAK) stock rose modestly by 0.4% on 4/8/24. The stock closed at $13.67. NORMAL trading volume accompanied the advance. The stock has been weak relative to the market over the last nine months and has declined -1.6% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, TAK is expected to continue to be a Value Builder.
Takeda Pharmaceutical has a current Value Trend Rating of C (High Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing very contradictory signals. Takeda Pharmaceutical has a very high Appreciation Score of 90 but a slightly negative Power Rating of 35, and the High Neutral Value Trend Rating results.
Be the first to comment